EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung-Ju Ahn iD, Kentaro Tanaka iD, Luis Paz-Ares iD, Robin Cornelissen iD, Nicolas Girard iD, Elvire Pons-Tostivint iD, David Vicente Baz, Shunichi Sugawara iD, Manuel Cobo iD, Maurice Pérol iD, Céline Mascaux iD, Elena Poddubskaya iD und 16 weitere

Journal of Clinical Oncology · 20.01.2025 · 43 (3) · 260-272

DOI: 10.1200/jco-24-01544 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2025. Verfasst von Myung-Ju Ahn und 27 weiteren Autor:innen. Beteiligte Einrichtung: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Docetaxel, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 261-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NSCLC). METHODS Patients received Dato-DXd 6 mg/kg or docetaxel 75 mg/m 2 once every 3 weeks. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Objective response rate, duration of response, and safety were secondary end points. RESULTS In total, 299 and 305 patients were randomly assigned to receive Dato-DXd or docetaxel, respectively. The median PFS was 4.4 months (95% CI, 4.2 to 5.6) with Dato-DXd and 3.7 months (95% CI, 2.9 to 4.2) with docetaxel (hazard ratio [HR], 0.75 [95% CI, 0.62 to 0.91]; P = .004). The median OS was 12.9 months (95% CI, 11.0 to 13.9) and 11.8 months (95% CI, 10.1 to 12.8), respectively (HR, 0.94 [95% CI, 0.78 to 1.14]; P = .530). In the prespecified nonsquamous histology subgroup, the median PFS was 5.5 versus 3.6 months (HR, 0.63 [95% CI, 0.51 to 0.79]) and the median OS was 14.6 versus 12.3 months (HR, 0.84 [95% CI, 0.68 to 1.05]). In the squamous histology subgroup, the median PFS was 2.8 versus 3.9 months (HR, 1.41 [95% CI, 0.95 to 2.08]) and the median OS was 7.6 versus 9.4 months (HR, 1.32 [95% CI, 0.91 to 1.92]). Grade ≥3 treatment-related adverse events occurred in 25.6% and 42.1% of patients, and any-grade adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8.8% and 4.1% of patients, in the Dato-DXd and docetaxel groups, respectively. CONCLUSION Dato-DXd significantly improved PFS versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology. OS showed a numerical benefit but did not reach statistical significance. No unexpected safety signals were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultProgression-Free SurvivalAged, 80 and over

Substanzen

Docetaxel

Autor:innen und Institutionen

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Kyushu University Hospital, Fukuoka, Japan.
  • Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Institut Curie, Paris, France.
  • University Hospital of Nantes, Nantes, France.

ORCID-Profile: Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons-Tostivint, Shunichi Sugawara, Manuel Cobo, Maurice Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Min Hee Hong, Enriqueta Felip, Richard Hall, Oscar Juan-Vidal, Daniel Brungs, Shun Lu, Marina Garassino, Michael Chargualaf, Yong Zhang, Paul Howarth, Deise Uema, Aaron Lisberg, Jacob Sands

Zitieren

APA

Ahn, M. J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Hong, M. H., Felip, E., Hall, R., Juan-Vidal, O., Brungs, D., …, & TROPION-Lung01 Trial Investigators (2025). Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. Journal of Clinical Oncology, 43(3), 260-272. https://doi.org/10.1200/jco-24-01544

Vancouver

Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. Journal of Clinical Oncology. 2025;43(3):260-272. doi:10.1200/jco-24-01544

BibTeX
@article{Ahn2025,
  author = {Ahn, Myung-Ju and Tanaka, Kentaro and Paz-Ares, Luis and Cornelissen, Robin and Girard, Nicolas and Pons-Tostivint, Elvire and Vicente Baz, David and Sugawara, Shunichi and Cobo, Manuel and Pérol, Maurice and Mascaux, Céline and Poddubskaya, Elena and Kitazono, Satoru and Hayashi, Hidetoshi and Hong, Min Hee and Felip, Enriqueta and Hall, Richard and Juan-Vidal, Oscar and Brungs, Daniel and Lu, Shun and Garassino, Marina and Chargualaf, Michael and Zhang, Yong and Howarth, Paul and Uema, Deise and Lisberg, Aaron and Sands, Jacob and TROPION-Lung01 Trial Investigators, TROPION-Lung01 Trial Investigators},
  title = {Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {3},
  pages = {260--272},
  doi = {10.1200/jco-24-01544}
}
Kostenlos starten →